[go: up one dir, main page]

CY1116313T1 - Αντισωματα εναντιον il-25 - Google Patents

Αντισωματα εναντιον il-25

Info

Publication number
CY1116313T1
CY1116313T1 CY20151100460T CY151100460T CY1116313T1 CY 1116313 T1 CY1116313 T1 CY 1116313T1 CY 20151100460 T CY20151100460 T CY 20151100460T CY 151100460 T CY151100460 T CY 151100460T CY 1116313 T1 CY1116313 T1 CY 1116313T1
Authority
CY
Cyprus
Prior art keywords
target
members
binding
antibodies
diseases
Prior art date
Application number
CY20151100460T
Other languages
English (en)
Inventor
David John Matthews
Jillian Barlow
Andrew Neil James Mckenzie
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Publication of CY1116313T1 publication Critical patent/CY1116313T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με περιοχές VH αντισώματος IL-25 και με μέλη δέσμευσης στόχου (π.χ., αντισώματα) που περιλαμβάνουν τέτοιες περιοχές VH αντισώματος και δεσμεύονται με IL-25. Η εφεύρεση σχετίζεται επίσης με συνθέσεις που περιλαμβάνουν μέλη δέσμευσης στόχου (π.χ., αντισώματα) που δεσμεύονται με IL-25, με μεθόδους παραγωγής τέτοιων μελών δέσμευσης στόχου, και με χρήσεις τέτοιων μελών δέσμευσης στόχου για την θεραπευτική ή προληπτική αγωγή ασθενειών και παθήσεων (π.χ., άσθματος, φλεγμονώδους νόσου εντέρων).
CY20151100460T 2008-09-30 2015-05-22 Αντισωματα εναντιον il-25 CY1116313T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10129308P 2008-09-30 2008-09-30
GBGB0817891.5A GB0817891D0 (en) 2008-09-30 2008-09-30 Antibodies against il-25
EP09795802.9A EP2344538B1 (en) 2008-09-30 2009-09-30 Antibodies against il-25

Publications (1)

Publication Number Publication Date
CY1116313T1 true CY1116313T1 (el) 2017-02-08

Family

ID=40019808

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100460T CY1116313T1 (el) 2008-09-30 2015-05-22 Αντισωματα εναντιον il-25

Country Status (22)

Country Link
US (1) US8658169B2 (el)
EP (1) EP2344538B1 (el)
JP (1) JP5719771B2 (el)
KR (1) KR101659452B1 (el)
CN (1) CN102245638B (el)
AU (1) AU2009299465B2 (el)
BR (1) BRPI0919062A2 (el)
CA (1) CA2739050C (el)
CY (1) CY1116313T1 (el)
DK (1) DK2344538T3 (el)
ES (1) ES2537226T3 (el)
GB (1) GB0817891D0 (el)
HR (1) HRP20150524T1 (el)
ME (1) ME02219B (el)
MX (1) MX2011003351A (el)
NZ (1) NZ592274A (el)
PL (1) PL2344538T3 (el)
PT (1) PT2344538E (el)
RS (1) RS54028B1 (el)
SI (1) SI2344538T1 (el)
SM (1) SMT201500144B (el)
WO (1) WO2010038155A2 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0707505D0 (en) 2007-04-18 2007-05-30 Medical Res Council Antibodies against il-25
GB0817891D0 (en) 2008-09-30 2008-11-05 Medical Res Council Antibodies against il-25
CN103097416B (zh) * 2010-03-30 2015-09-09 詹森生物科技公司 人源化il-25抗体
US9353153B2 (en) 2012-02-09 2016-05-31 Riken Cyclic RNA and protein production method
CN103792375B (zh) * 2014-01-29 2017-07-07 华中科技大学同济医学院附属同济医院 外周血白细胞介素25水平在哮喘分型中的应用及分型方法
WO2016049000A2 (en) * 2014-09-23 2016-03-31 Regeneron Pharmaceuticals, Inc. Anti-il-25 antibodies and uses thereof
JP7140397B2 (ja) 2016-03-16 2022-09-21 アベオメ コーポレーション Ｉｌ－２５に対する中和モノクローナル抗体及びその使用
WO2018017864A2 (en) * 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
WO2018018082A1 (en) 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor
AU2018450414B2 (en) 2018-11-19 2025-10-16 Beijing Kanova Biopharmaceutical Co., Ltd. Anti-IL-25 antibodies and use thereof
GB202018015D0 (en) 2020-11-16 2020-12-30 Res & Innovation Uk Composition and methods for the treatment of intestinal cancer
EP4370157A1 (en) 2021-07-14 2024-05-22 Lycia Therapeutics, Inc. Asgpr cell surface receptor binding compounds and conjugates
JP2025526767A (ja) * 2022-08-12 2025-08-15 ライシア セラピューティクス， インコーポレイテッド リソソーム標的化分解のための二重特異性抗体及び構築物、ならびにそれらの使用方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5071972A (en) 1986-01-31 1991-12-10 Genetics Institute, Inc. DNA sequences encoding novel thrombolytic proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0276846A3 (en) 1987-01-29 1989-07-26 Zymogenetics, Inc. Colony-stimulating factor derivatives
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US6569645B2 (en) 1999-05-14 2003-05-27 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1631590B1 (en) 2003-04-23 2011-07-27 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
CA2599754C (en) 2005-03-08 2012-06-19 Genesense Technologies Inc. Use of interleukin 17e for the treatment of cancer
WO2007044450A2 (en) * 2005-10-06 2007-04-19 Baylor Research Institute Compositions and methods for the treatment of cancer
GB0707505D0 (en) * 2007-04-18 2007-05-30 Medical Res Council Antibodies against il-25
GB0817891D0 (en) 2008-09-30 2008-11-05 Medical Res Council Antibodies against il-25
CN103097416B (zh) * 2010-03-30 2015-09-09 詹森生物科技公司 人源化il-25抗体
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
PL2344538T3 (pl) 2015-10-30
PT2344538E (pt) 2015-06-19
ME02219B (me) 2016-02-20
KR20110086013A (ko) 2011-07-27
JP2012503979A (ja) 2012-02-16
MX2011003351A (es) 2011-05-25
CN102245638A (zh) 2011-11-16
KR101659452B1 (ko) 2016-09-23
ES2537226T3 (es) 2015-06-03
US8658169B2 (en) 2014-02-25
HK1154022A1 (en) 2012-04-13
GB0817891D0 (en) 2008-11-05
EP2344538A2 (en) 2011-07-20
HRP20150524T1 (hr) 2015-08-14
CA2739050A1 (en) 2010-04-08
CA2739050C (en) 2018-05-29
NZ592274A (en) 2012-08-31
WO2010038155A2 (en) 2010-04-08
AU2009299465B2 (en) 2012-07-26
SMT201500144B (it) 2015-09-07
JP5719771B2 (ja) 2015-05-20
RS54028B1 (sr) 2015-10-30
DK2344538T3 (en) 2015-06-01
SI2344538T1 (sl) 2015-07-31
BRPI0919062A2 (pt) 2015-12-15
WO2010038155A3 (en) 2010-05-27
US20110250195A1 (en) 2011-10-13
EP2344538B1 (en) 2015-02-25
AU2009299465A1 (en) 2010-04-08
CN102245638B (zh) 2014-10-22

Similar Documents

Publication Publication Date Title
CY1116313T1 (el) Αντισωματα εναντιον il-25
CY1124209T1 (el) Συνθεσεις anti-cgrp και χρησεις αυτων
CY1120468T1 (el) Εξανθρωπισμενα αντισωματα il-25
CY1119994T1 (el) Συνθεσεις και μεθοδοι για αυξηση της μυϊκης μαζας και της μυϊκης δυναμης ανταγωνιζοντας ειδικα ton gdf8 και/ή την ακτιβινη α
CY1122278T1 (el) Αντι il-36r αντισωματα
CY1124412T1 (el) Aνti-dkk-1 αντισωματα
CY1120670T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi)
CY1118691T1 (el) Συνθεσεις και μεθοδοι χρησης για αντισωματα κατα σκληροστινης
MX369148B (es) Agentes de unión kir3dl2.
CY1118014T1 (el) Aνti-il-23 αντισωματα
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
CY1118244T1 (el) Αντισωματα κατα της il-25
EA201100923A1 (ru) Антитела человека против тканевого фактора
ECSP10010580A (es) Inmunoglobulinas duales de dominio variable y sus aplicaciones
CY1121167T1 (el) Βελτιωμενα αντισωματα εναντι της ανθρωπινης φρακταλκινης και χρησεις αυτων
EP2373692A4 (en) IMMUNOGLOBULINE WITH DOUBLE VARIABLE DOMAIN AND ITS USE
ECSP10010644A (es) Inmunoglobulinas duales de dominio variable y sus aplicaciones
EA200970874A1 (ru) Антитела против склеростина
ECSP12012272A (es) Proteínas que se unen al tnf-?
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
MX2011011754A (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b.
MX374128B (es) Formulaciones de moléculas de unión a antígeno de dominio sencillo.
SG178602A1 (en) Dual variable domain immunoglobulins and uses thereof
PH12012500774A1 (en) Dual variable domain immunoglobulins and uses thereof
PH12012500815A1 (en) Dual variable domain immunoglobulins and uses thereof